Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizu

UCB, a global biopharmaceutical company, today announced the first analyses of pooled data...

Related Keywords

Germany , Belgium , Brussels , Bruxelles Capitale , Berlin , Hidradenitis Suppurativa , Emmanuel Caeymaex , Klinikum Dessau , J Clin Pharmacol , Nicole Herga , Antje Witte , European Academy Of Dermatology , Drug Administration , Us Communications , European Hidradenitis Suppurativa Foundation , Brandenburg Medical School , International Hidradenitis Suppurativa Severity Score System , Immunology Solutions , Twitter , Analysis Presented , Bimekizumab Achieved High Thresholds , Clinical Response , Executive Vice President , Professor Christos , Founding Professor , Last Observation Carried , Euronext Brussels , Study Participants With Moderate , Severe Hidradenitis Suppurativa , Rev Dis , Perceived Stigma , Self Stigma In Patients With Hidradenitis , Clin Cosmet Investig , Its Effect ,